Gemini Therapeutics Stock Forecast, Price & News

-0.46 (-3.69 %)
(As of 05/6/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume111,304 shs
Average Volume270,885 shs
Market Capitalization$515.99 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive GMTX News and Ratings via Email

Sign-up to receive the latest news and ratings for Gemini Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology
Current SymbolNASDAQ:GMTX
Phone617 678 3113
Year FoundedN/A

Sales & Book Value

Annual SalesN/A





Market Cap$515.99 million
Next Earnings DateN/A


See More Headlines
Gemini Therapeutics logo

About Gemini Therapeutics

Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD) and linked ocular disorders. Its lead candidate is GEM103, a recombinant form of the human complement factor H protein that is in a Phase 2a trials in dry AMD patients with a complement factor H protein risk variant. The company was founded in 2015 and is based in Cambridge, Massachusetts.


Overall MarketRank

1.70 out of 5 stars

Medical Sector

264th out of 2,041 stocks

Biotechnology Industry

23rd out of 157 stocks

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Gemini Therapeutics (NASDAQ:GMTX) Frequently Asked Questions

Is Gemini Therapeutics a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Gemini Therapeutics in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Gemini Therapeutics stock.
View analyst ratings for Gemini Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Gemini Therapeutics?

Wall Street analysts have given Gemini Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Gemini Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What price target have analysts set for GMTX?

4 brokers have issued 1 year price targets for Gemini Therapeutics' stock. Their forecasts range from $20.00 to $25.00. On average, they expect Gemini Therapeutics' share price to reach $22.00 in the next twelve months. This suggests a possible upside of 83.3% from the stock's current price.
View analysts' price targets for Gemini Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Gemini Therapeutics' key executives?

Gemini Therapeutics' management team includes the following people:
  • Mr. Jason Patrick Meyenburg M.B.A., M.D., CEO, Pres & Director (Age 44, Pay $530.29k)
  • Dr. Scott Lauder Ph.D., Chief Technology Officer (Age 57, Pay $480.3k)
  • Dr. Marc E. Uknis F.A.C.S., M.D., Chief Medical Officer (Age 56, Pay $397.39k)
  • Mr. Brian Piekos, CFO & Principal Accounting and Financial Officer (Age 46)
  • Dr. Walter Strapps, Chief Scientific Officer
  • Ms. Precillia Redmond, Chief People Officer

Who are some of Gemini Therapeutics' key competitors?

What is Gemini Therapeutics' stock symbol?

Gemini Therapeutics trades on the NASDAQ under the ticker symbol "GMTX."

Who are Gemini Therapeutics' major shareholders?

Gemini Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include Altium Capital Management LP (0.47%).

Which major investors are buying Gemini Therapeutics stock?

GMTX stock was bought by a variety of institutional investors in the last quarter, including Altium Capital Management LP.

How do I buy shares of Gemini Therapeutics?

Shares of GMTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Gemini Therapeutics' stock price today?

One share of GMTX stock can currently be purchased for approximately $12.00.

How much money does Gemini Therapeutics make?

Gemini Therapeutics has a market capitalization of $515.99 million.

How many employees does Gemini Therapeutics have?

Gemini Therapeutics employs 29 workers across the globe.

What is Gemini Therapeutics' official website?

The official website for Gemini Therapeutics is

How can I contact Gemini Therapeutics?

The company can be reached via phone at 617 678 3113.

This page was last updated on 5/7/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.